Insufficient scRNA-seq data for expression of CYP17A1 at single-cell level.
Insufficient scRNA-seq data for expression of CYP17A1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 703602.92 | 258 / 258 | 55% | 591.48 | 127 / 230 |
liver | 100% | 357.10 | 226 / 226 | 48% | 18.47 | 195 / 406 |
ovary | 97% | 1737.25 | 174 / 180 | 30% | 1.38 | 130 / 430 |
kidney | 100% | 995.93 | 89 / 89 | 23% | 4.78 | 205 / 901 |
thymus | 100% | 461.08 | 653 / 653 | 18% | 0.42 | 111 / 605 |
muscle | 98% | 165.77 | 790 / 803 | 0% | 0 | 0 / 0 |
stomach | 91% | 109.16 | 327 / 359 | 6% | 0.30 | 16 / 286 |
blood vessel | 94% | 158.05 | 1260 / 1335 | 0% | 0 | 0 / 0 |
uterus | 93% | 139.68 | 158 / 170 | 1% | 0.04 | 6 / 459 |
prostate | 89% | 92.96 | 219 / 245 | 0% | 0.01 | 2 / 502 |
spleen | 89% | 103.85 | 214 / 241 | 0% | 0 | 0 / 0 |
brain | 88% | 107.64 | 2331 / 2642 | 0% | 0.00 | 3 / 705 |
breast | 87% | 90.45 | 401 / 459 | 1% | 0.22 | 7 / 1118 |
lung | 79% | 79.94 | 459 / 578 | 2% | 0.37 | 21 / 1155 |
adipose | 80% | 77.30 | 960 / 1204 | 0% | 0 | 0 / 0 |
esophagus | 73% | 81.01 | 1057 / 1445 | 4% | 0.45 | 8 / 183 |
pancreas | 74% | 92.56 | 242 / 328 | 1% | 2.74 | 1 / 178 |
bladder | 71% | 82.24 | 15 / 21 | 1% | 0.02 | 4 / 504 |
intestine | 67% | 60.78 | 649 / 966 | 4% | 1.75 | 21 / 527 |
skin | 61% | 68.67 | 1107 / 1809 | 1% | 4.86 | 6 / 472 |
heart | 49% | 57.62 | 419 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 42% | 64.02 | 389 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0042448 | Biological process | progesterone metabolic process |
GO_0042446 | Biological process | hormone biosynthetic process |
GO_0006704 | Biological process | glucocorticoid biosynthetic process |
GO_0008202 | Biological process | steroid metabolic process |
GO_0006702 | Biological process | androgen biosynthetic process |
GO_0007548 | Biological process | sex differentiation |
GO_0006694 | Biological process | steroid biosynthetic process |
GO_0030424 | Cellular component | axon |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0043025 | Cellular component | neuronal cell body |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0019825 | Molecular function | oxygen binding |
GO_0005506 | Molecular function | iron ion binding |
GO_0020037 | Molecular function | heme binding |
GO_0004508 | Molecular function | steroid 17-alpha-monooxygenase activity |
Gene name | CYP17A1 |
Protein name | Steroid 17-alpha-hydroxylase/17,20 lyase (EC 1.14.14.19) (EC 1.14.14.32) (CYPXVII) (Cytochrome P450 17A1) (Cytochrome P450-C17) (Steroid 17-alpha-monooxygenase) Steroid 17-alpha-monooxygenase Steroid 17-alpha-hydroxylase/17,20 lyase (EC 1.14.99.9) Steroid 17-alpha-hydroxylase/17,20 lyase (EC 1.14.14.19) (17-alpha-hydroxyprogesterone aldolase) (EC 1.14.14.32) (CYPXVII) (Cytochrome P450 17A1) (Cytochrome P450-C17) (Cytochrome P450c17) (Steroid 17-alpha-monooxygenase) |
Synonyms | CYP17 hCG_22577 S17AH |
Description | FUNCTION: A cytochrome P450 monooxygenase involved in corticoid and androgen biosynthesis . Catalyzes 17-alpha hydroxylation of C21 steroids, which is common for both pathways. A second oxidative step, required only for androgen synthesis, involves an acyl-carbon cleavage. The 17-alpha hydroxy intermediates, as part of adrenal glucocorticoids biosynthesis pathway, are precursors of cortisol (Probable). Hydroxylates steroid hormones, pregnenolone and progesterone to form 17-alpha hydroxy metabolites, followed by the cleavage of the C17-C20 bond to form C19 steroids, dehydroepiandrosterone (DHEA) and androstenedione . Has 16-alpha hydroxylase activity. Catalyzes 16-alpha hydroxylation of 17-alpha hydroxy pregnenolone, followed by the cleavage of the C17-C20 bond to form 16-alpha-hydroxy DHEA . Also 16-alpha hydroxylates androgens, relevant for estriol synthesis . Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) . . |
Accessions | ENST00000638272.1 A0A1W2PRK7 ENST00000639393.1 ENST00000638190.1 A0A1W2PRY0 P05093 A0A1L7H7S6 C7F7K7 ENST00000369887.4 A0A1W2PQT5 A0A1L7H7K7 Q1HB44 A0A1W2PQ28 ENST00000638971.1 A0A1L7H7L1 |